Fluticasone Propionate And Salmeterol
Product Images NDC 53002-1568

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 53002-1568). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

Chemical structure diagram of the active ingredients in Fluticasone Propionate and Salmeterol DISKUS, showing molecular bonds and atom arrangement relevant to these compounds.*

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

Chemical structure of the active ingredients in Fluticasone Propionate and Salmeterol DISKUS, showing molecular diagrams of key compounds present in the product.*

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

Line graph showing the percentage change in FEV1 over a 12-week period for four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, Salmeterol 50 mcg twice daily, and Placebo. The graph includes sample sizes at different time points and compares lung function improvement among the treatment groups.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

A line graph showing the percentage change in FEV1 over 12 hours after dosing on Day 1 baseline. It compares four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo. The y-axis represents % change in FEV1, and the x-axis represents time in hours from baseline.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

A line chart showing the percentage change in FEV1 relative to Day 1 baseline over 12 hours. It compares four groups: Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo, with sample sizes noted for each group. The chart illustrates the time course of lung function changes post-treatment.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

A line graph depicting percent change in FEV1 over 24 weeks for three groups: Fluticasone propionate/salmeterol DISKUS 250/50 mcg twice daily, Salmeterol 50 mcg twice daily, and Placebo. The graph shows data points and trends with corresponding baseline FEV1 values noted for each group, along with participant counts at various time points.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

A line graph showing the percentage change in FEV1 over time for three groups: Fluticasone propionate/salmeterol 250/50 mcg twice daily, Fluticasone propionate 250 mcg twice daily, and placebo. The x-axis represents days and weeks, and the y-axis indicates percent change in FEV1. The graph also includes participant counts (N) at specific time points for each group.*

FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

An illustration of the Fluticasone Propionate and Salmeterol DISKUS inhaler showing labeled parts: outer case, counter, thumb grip, lever, and mouthpiece. The label on the device indicates 60 blisters containing 100 mcg fluticasone propionate and 50 mcg salmeterol per inhalation dose.*

FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

An instructional image depicting a person holding a Fluticasone Propionate and Salmeterol DISKUS inhaler. The hands are shown demonstrating the opening mechanism, with a large arrow indicating the direction to slide the mouthpiece open.*

FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

An instructional illustration showing a person's hand holding a DISKUS inhaler, demonstrating the motion of sliding the lever to prepare the device for inhalation, indicated by a horizontal arrow pointing to the right.*

FDA Label Image

Figure D (Fp Sal Spl Graphic 11)

An instructional illustration showing a woman holding a Fluticasone Propionate and Salmeterol DISKUS inhaler near her mouth, demonstrating the proper technique for using the inhaler device.*

FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

Black and white illustration of a woman using an inhaler device, holding it to her mouth in the correct inhalation position. The image demonstrates proper use of an inhaler, likely representing the Fluticasone Propionate and Salmeterol DISKUS inhalation device.*

FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

An instructional illustration demonstrating how to hold and slide the Fluticasone Propionate and Salmeterol DISKUS inhaler. Two hands are shown gripping the inhaler while an arrow indicates the direction to slide the device to open or activate it for use.*

FDA Label Image

Figure G (Fp Sal Spl Graphic 14)

An illustration showing a person exhaling vapor or mist into a kitchen sink faucet area, with a half-full glass of water nearby. The image suggests a demonstration or instructional context related to inhalation or respiratory medication use.*

FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

Fluticasone Propionate and Salmeterol DISKUS inhalation powder device labeled with strength 100 mcg/50 mcg. The device is predominantly gray with a circular white label indicating the dosage and quantity (50 blisters). The image includes a blister marked with the number 5. The product is labeled by RPK Pharmaceuticals, Inc.*

FDA Label Image

Label Image (Lbl530021568)

Fluticasone Propionate and Salmeterol DISKUS 100/50 inhalation powder, containing 60 doses per inhaler, labeled for oral inhalation use. The packaging directs use twice daily or as directed and includes sections for clinic and prescription information. The product is distributed by RPK Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.